EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieStudienprotokollOpen access

Effect of a personalised mobile health intervention using artificial intelligence (the WARIFA app) versus a non-personalised intervention on user-defined objectives, healthy lifestyles and management of type 1 diabetes (T1D): a randomised controlled trial protocol (Preprint)

Carmelo Betancort Acosta iD, Garlene Zamora Zamorano iD, María Luisa Álvarez Malé iD, Lilisbeth Perestelo-Perez iD, Alezandra Torres Castaño iD, Marit B Veierød iD, Kristina Reyes Suárez iD, Alejandro Déniz García iD, Eirik Årsand iD, Inger Torhild Gram iD, Maja-Lisa Løchen iD, Cristina Soguero-Ruiz iD and 8 more

JMIR Research Protocols · 2025

DOI: 10.2196/84510 ↗

At a glance

Randomisierte kontrollierte Studie in JMIR Research Protocols, 2025. Written by Carmelo Betancort Acosta and 19 co-authors. Institution: Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, Spai…. Major MEDLINE topics: Artificial Intelligence, Diabetes Mellitus, Type 1, Digital Health, Healthy Lifestyle. 45 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Noncommunicable diseases are the leading cause of death worldwide. Cardiovascular and respiratory diseases, cancer, and type 2 diabetes share common risk factors that can be addressed: physical activity, a healthy diet, and avoiding smoking and alcohol. The Watching the Risk Factors (WARIFA) mobile health app was created for general health awareness and to support users in adopting healthier behaviors, as well as to support type 1 diabetes (T1D) self-management. OBJECTIVE: This study aims to evaluate the effectiveness of the WARIFA app with personalized artificial intelligence (AI)-driven messages, compared to a nonpersonalized version, in promoting health-related behavior change among the general population and individuals with T1D. METHODS: A total of 108 European participants, including individuals with T1D, were to be randomized (computer-generated sequence, double-blind, 1:1 ratio) to an intervention or control group. In the intervention group, participants used the WARIFA app with personalized messages and the use of AI. This applied to certain functionalities, such as providing recommendations on healthy dietary habits based on food logging and offering advice and encouragement through daily step tracking. It also provided risk predictions for cardiovascular and respiratory diseases, cancer, and type 2 diabetes. Participants with T1D were offered glucose predictions based on previous measurements. In the control group, participants used a WARIFA app without personalized messages or AI. Both WARIFA app versions offered access to air quality and UV index information for the geographical area, as well as displaying physical activity in the form of daily steps and sleep hours, as well as glucose results for participants with T1D. Both groups were provided with an activity monitor and used the WARIFA app for 8-12 weeks. The primary outcome is a self-defined goal, chosen from a set of proposed objectives at baseline and assessed at the end of the study using a Likert scale (1 to 10 points, 0 being no achievement at all and 10 being full achievement of the objective). Secondary outcomes include: engagement with the app, changes in lifestyle behavior, body composition, lipid profile, glycated hemoglobin (T1D only), hypoglycemic events (T1D only), and health-related quality of life, as well as acquired knowledge, self-efficacy, and usability. RESULTS: The clinical trial took place between January and June 2025. A total of 88 participants were finally recruited. The data are being analyzed, and the results are expected to be published in 2026. CONCLUSIONS: There is evidence that improving lifestyle behavior can prevent noncommunicable diseases. In this study, we aim to evaluate the effectiveness of the WARIFA app to improve lifestyle behaviors and T1D management. TRIAL REGISTRATION: ClinicalTrials.gov NCT06918444; https://clinicaltrials.gov/study/NCT06918444. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/84510.

Subjects

MeSH terms (MEDLINE)

Artificial IntelligenceDiabetes Mellitus, Type 1Digital HealthHealthy LifestyleMobile ApplicationsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodTelemedicineRandomized Controlled Trials as Topic

Author keywords

artificial intelligencebehavior changelifestylemHealth appmobile healthnoncommunicable diseasestype 1 diabetesuser-centered

Authors and institutions

  • Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain.
  • The University Institute of Biomedical and Healthcare Research, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain.
  • Instituto de Investigación Sanitaria de Canarias, Las Palmas de Gran Canaria, Spain.
  • Evaluation Unit, Canary Islands Health Service, Santa Cruz de Tenerife, Spain.
  • Network for Research on Chronicity, Primary Care, and Health Promotion, Santa Cruz de Tenerife, Spain.
  • Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Las Palmas de Gran Canaria, Spain.

ORCID profiles: Carmelo Betancort Acosta, Garlene Zamora Zamorano, María Luisa Álvarez Malé, Lilisbeth Perestelo-Perez, Alezandra Torres Castaño, Marit B Veierød, Kristina Reyes Suárez, Alejandro Déniz García, Eirik Årsand, Inger Torhild Gram, Maja-Lisa Løchen, Cristina Soguero-Ruiz, André Henriksen, Antonio J Rodríguez Almeida, Miroslav Muzny, Reetta Välimäki, Thomas Schopf, Himar Fabelo, Conceição Granja, Ana M Wägner

Cite

APA

Betancort Acosta, C., Zamora Zamorano, G., Álvarez Malé, M. L., Perestelo-Perez, L., Torres Castaño, A., Veierød, M. B., Reyes Suárez, K., Déniz García, A., Årsand, E., Torhild Gram, I., Løchen, M. L., Soguero-Ruiz, C., Henriksen, A., Rodríguez Almeida, A. J., Muzny, M., Välimäki, R., Schopf, T., Fabelo, H., Granja, C., & Wägner, A. M. (2025). Effect of a personalised mobile health intervention using artificial intelligence (the WARIFA app) versus a non-personalised intervention on user-defined objectives, healthy lifestyles and management of type 1 diabetes (T1D): a randomised controlled trial protocol (Preprint). JMIR Research Protocols. https://doi.org/10.2196/84510

Vancouver

Betancort Acosta C, Zamora Zamorano G, Álvarez Malé ML, Perestelo-Perez L, Torres Castaño A, Veierød MB, et al. Effect of a personalised mobile health intervention using artificial intelligence (the WARIFA app) versus a non-personalised intervention on user-defined objectives, healthy lifestyles and management of type 1 diabetes (T1D): a randomised controlled trial protocol (Preprint). JMIR Research Protocols. 2025. doi:10.2196/84510

BibTeX
@article{BetancortAcosta2025,
  author = {Betancort Acosta, Carmelo and Zamora Zamorano, Garlene and Álvarez Malé, María Luisa and Perestelo-Perez, Lilisbeth and Torres Castaño, Alezandra and Veierød, Marit B and Reyes Suárez, Kristina and Déniz García, Alejandro and Årsand, Eirik and Torhild Gram, Inger and Løchen, Maja-Lisa and Soguero-Ruiz, Cristina and Henriksen, André and Rodríguez Almeida, Antonio J and Muzny, Miroslav and Välimäki, Reetta and Schopf, Thomas and Fabelo, Himar and Granja, Conceição and Wägner, Ana M},
  title = {Effect of a personalised mobile health intervention using artificial intelligence (the WARIFA app) versus a non-personalised intervention on user-defined objectives, healthy lifestyles and management of type 1 diabetes (T1D): a randomised controlled trial protocol (Preprint)},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/84510}
}
Start for free →